ALEC Latest Headlines

Alector’s AL137 Shows Potential to Differentiate Through Safer, More Convenient, and Higher Brain Exposure in Alzheimer’s Disease

at www.tipranks.com (Fri, 6-Nov 10:06 AM)

Alector’s AL137 Pipeline and Financial Runway Support Buy Rating; $6 Price Target Maintained

at www.tipranks.com (Fri, 6-Nov 9:31 AM)

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Lyell Immunopharma (LYEL) and Alector (ALEC)

at www.tipranks.com (Fri, 6-Nov 7:50 AM)

Alector GAAP EPS of $1.11 beats by $1.10

at seekingalpha.com (Thu, 5-Nov 5:55 PM)

Alector Ties Up With Genentech on Brain-Penetrant GCase Therapy, Putting $1.27B in Potential Deal Value on the Table

Market Chameleon (Mon, 5-Oct 9:54 AM)

Alector licenses brain-penetrant AL050 to Genentech, led by $100 million upfront and up to $1.17 billion in milestones

Market Chameleon (Mon, 5-Oct 8:13 AM)